MCID: CHR176
MIFTS: 25

Chromophil Renal Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Chromophil Renal Cell Carcinoma

MalaCards integrated aliases for Chromophil Renal Cell Carcinoma:

Name: Chromophil Renal Cell Carcinoma 54
Papillary Renal Cell Carcinoma 74
Chromophil Rcc 54

Classifications:



External Ids:

UMLS 74 C1306837

Summaries for Chromophil Renal Cell Carcinoma

MalaCards based summary : Chromophil Renal Cell Carcinoma, also known as papillary renal cell carcinoma, is related to renal cell carcinoma, papillary, 1 and renal cell carcinoma, nonpapillary, and has symptoms including flank pain The drugs Sunitinib and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and prostate.

Related Diseases for Chromophil Renal Cell Carcinoma

Diseases related to Chromophil Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, papillary, 1 11.4
2 renal cell carcinoma, nonpapillary 10.6

Symptoms & Phenotypes for Chromophil Renal Cell Carcinoma

UMLS symptoms related to Chromophil Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Chromophil Renal Cell Carcinoma

Drugs for Chromophil Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 3,Phase 2 557795-19-4, 341031-54-7 5329102
2
Sorafenib Approved, Investigational Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
3
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 3,Phase 2 53123-88-9 46835353 5284616 6436030
5
Everolimus Approved Phase 3,Phase 2 159351-69-6 70789204 6442177
6 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
7 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
13 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
15
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
16
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
17
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
18
Gemcitabine Approved Phase 2 95058-81-4 60750
19
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
20
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
21
leucovorin Approved Phase 2 58-05-9 143 6006
22
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
23
Lenograstim Approved, Investigational Phase 2 135968-09-1
24
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
25
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
26
Etoposide Approved Phase 2 33419-42-0 36462
27
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
28
Dactinomycin Approved, Investigational Phase 2 50-76-0 457193 2019
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
31
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
32
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
33
nivolumab Approved Phase 2 946414-94-4
34
Ipilimumab Approved Phase 2 477202-00-9
35
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
36
Mycophenolic acid Approved Phase 1, Phase 2,Phase 2,Not Applicable 24280-93-1 446541
37
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 24356-66-9 21704 32326
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
40
Doxil Approved June 1999 Phase 2 31703
41
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
42
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
43 Antibodies Phase 2,Phase 1
44 Endothelial Growth Factors Phase 2
45 Immunoglobulins Phase 2,Phase 1
46 Antineoplastic Agents, Immunological Phase 2,Phase 1
47 Antibodies, Monoclonal Phase 2
48 Mitogens Phase 2
49 Immunoglobulin G Phase 2
50 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
2 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
3 Savolitinib vs. Sunitinib in MET-driven PRCC Active, not recruiting NCT03091192 Phase 3 Savolitinib;Sunitinib
4 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
5 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2 sunitinib malate
6 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Completed NCT00726323 Phase 2 foretinib (formerly GSK1363089 or XL880)
7 Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Completed NCT01688973 Phase 2 Erlotinib Hydrochloride;Tivantinib
8 Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer Completed NCT00060307 Phase 2 erlotinib hydrochloride
9 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Completed NCT00459875 Phase 2 sunitinib malate
10 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2 RAD001
11 Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT00605618 Phase 1, Phase 2 BMS-777607
12 Bortezomib in Treating Patients With Metastatic Kidney Cancer Completed NCT00276614 Phase 2 bortezomib
13 Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer Completed NCT01727089 Phase 2
14 Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer Completed NCT00401128 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
15 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery Completed NCT00459979 Phase 2 sunitinib malate
16 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00027573 Phase 2 cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
17 Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Completed NCT00126503 Phase 1, Phase 2 Sorafenib Tosylate
18 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
19 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T Completed NCT01174368 Phase 2
20 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer Recruiting NCT02019693 Phase 2 INC280
21 Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Recruiting NCT02495103 Phase 1, Phase 2 Vandetanib;Metformin;Vandetanib/Metformin
22 A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer Recruiting NCT01130519 Phase 2 Bevacizumab;Erlotinib
23 Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Recruiting NCT02761057 Phase 2 Cabozantinib;Cabozantinib S-malate;Crizotinib;Savolitinib;Sunitinib;Sunitinib Malate
24 ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) Recruiting NCT03685448 Phase 2 Cabozantinib
25 Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Recruiting NCT03177239 Phase 2 Nivolumab;Ipilimumab
26 Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Recruiting NCT03541902 Phase 2 Cabozantinib;Sunitinib Malate
27 Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
28 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2
29 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment Recruiting NCT03200717 Phase 2 pazopanib
30 A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) Active, not recruiting NCT02127710 Phase 2 AZD6094
31 Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma Active, not recruiting NCT02489695 Phase 2 axitinib
32 CREATE: Cross-tumoral Phase 2 With Crizotinib Active, not recruiting NCT01524926 Phase 2 Crizotinib (PF-02341066)
33 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
35 Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT01164228 Phase 2 gemcitabine hydrochloride;sunitinib malate
36 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01767636 Phase 2 Pazopanib Hydrochloride
37 Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer Active, not recruiting NCT02046174 Phase 2
38 Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Terminated NCT00601926 Phase 2
39 Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer Terminated NCT00323791 Phase 2 gemcitabine hydrochloride;imatinib mesylate
40 Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Terminated NCT00098618 Phase 2 sorafenib tosylate
41 Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer Completed NCT00283075 Phase 1
42 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting NCT03319628 Phase 1 XMT-1536
43 HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma Terminated NCT02947152 Phase 1 HKT288
44 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Terminated NCT02837991 Phase 1 CDX-014
45 DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE Completed NCT00900536
46 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00005799 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Chromophil Renal Cell Carcinoma

Genetic Tests for Chromophil Renal Cell Carcinoma

Anatomical Context for Chromophil Renal Cell Carcinoma

MalaCards organs/tissues related to Chromophil Renal Cell Carcinoma:

42
Kidney, Endothelial, Prostate, Thyroid, Lymph Node, Brain, Neutrophil

Publications for Chromophil Renal Cell Carcinoma

Articles related to Chromophil Renal Cell Carcinoma:

(show top 50) (show all 452)
# Title Authors Year
1
Clear Cell Papillary Renal Cell Carcinoma. ( 30672334 )
2019
2
A Case of Clear Cell Papillary Renal Cell Carcinoma With Prominent Glycogen-Containing Intranuclear Inclusions. ( 30813834 )
2019
3
Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. ( 30924768 )
2019
4
Cytomorphologic comparison of type 1 and type 2 papillary renal cell carcinoma: A retrospective analysis of 28 cases. ( 31091016 )
2019
5
Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma. ( 30957192 )
2019
6
Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma. ( 30977386 )
2019
7
The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets. ( 30816528 )
2019
8
Syntaxin 6: A novel predictive and prognostic biomarker in papillary renal cell carcinoma. ( 30816681 )
2019
9
A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma. ( 30822312 )
2019
10
Potential Oncogenic Role of the Papillary Renal Cell Carcinoma Gene in Non-Small Cell Lung Cancers. ( 30900418 )
2019
11
External validation of the updated Leibovich prognostic models for clear cell and papillary renal cell carcinoma in an Asian population. ( 30905510 )
2019
12
Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases. ( 30755496 )
2019
13
Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. ( 30448104 )
2019
14
Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. ( 30507262 )
2019
15
Papillary Renal Cell Carcinoma (PRCC): An Update. ( 30507616 )
2019
16
Primary Extrarenal Type 2 Papillary Renal Cell Carcinoma: A Case Report. ( 30395891 )
2019
17
High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. ( 30121370 )
2019
18
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. ( 28695322 )
2018
19
Differentiation between papillary renal cell carcinoma and fat-poor angiomyolipoma: a preliminary study assessing detection of intratumoral hemorrhage with chemical shift MRI and T2*-weighted gradient echo. ( 29069911 )
2018
20
Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma. ( 29561526 )
2018
21
Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex. ( 29180251 )
2018
22
Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10-year retrospective study from two institutions. ( 29963177 )
2018
23
Expression of vitamin D receptor in clear cell papillary renal cell carcinoma. ( 29966830 )
2018
24
Clear cell papillary renal cell carcinoma - An indolent subtype of renal tumor. ( 30037497 )
2018
25
Clear cell papillary renal cell carcinoma: A case report and review of the literature. ( 30596034 )
2018
26
Takotsubo syndrome induced by malignant pheochromocytoma in a patient with type 2 papillary renal cell carcinoma - a case report. ( 29785166 )
2018
27
A back-to-back tumor composed of papillary renal cell carcinoma and oncocytoma treated by laparoscopic partial nephrectomy: a case report. ( 29779490 )
2018
28
Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases. ( 30072012 )
2018
29
Combined Papillary Renal Cell Carcinoma with Neuroendocrine Differentiation and Mucinous Tubular and Spindle Cell Carcinoma. ( 30693127 )
2018
30
Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features. ( 29462091 )
2018
31
Chondroid and osseous metaplasia in an incidental type II papillary renal cell carcinoma with extensive solid areas: an unraveled molecular character. ( 30918553 )
2018
32
Papillary renal cell carcinoma in contrast-enhanced ultrasound (CEUS) - a diagnostic performance study. ( 30562896 )
2018
33
The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. ( 30474436 )
2018
34
Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma. ( 30199877 )
2018
35
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma. ( 30214555 )
2018
36
Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. ( 30224330 )
2018
37
Differentiation of Papillary Renal Cell Carcinoma Subtypes on MRI: Qualitative and Texture Analysis. ( 30240294 )
2018
38
Prevalence of Low-Attenuation Homogeneous Papillary Renal Cell Carcinoma Mimicking Renal Cysts on CT. ( 30240301 )
2018
39
Rare isolated synchronous splenic metastasis in a patient with type II papillary renal cell carcinoma. ( 30264005 )
2018
40
Answer to comment on manuscript "Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients". ( 30022407 )
2018
41
Diagnostic Accuracy of MRI for Detection of Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. ( 30063398 )
2018
42
Type 1 Papillary Renal Cell Carcinoma Presenting as an Infected Benign Renal Cyst: an Uncommon Presentation. ( 29887714 )
2018
43
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. ( 29896907 )
2018
44
Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2? ( 29932401 )
2018
45
Machine learning models to predict the progression from early to late stages of papillary renal cell carcinoma. ( 29990647 )
2018
46
GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma. ( 29865032 )
2018
47
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. ( 29685646 )
2018
48
Re: Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. ( 29704948 )
2018
49
Type II papillary renal cell carcinoma with heterotrophic ossification: a case report. ( 29493352 )
2018
50
Recurrent papillary renal cell carcinoma with concomitant ipsilateral upper urinary tract urothelial carcinoma and metachronous urothelial carcinoma of the bladder. ( 29379740 )
2018

Variations for Chromophil Renal Cell Carcinoma

Expression for Chromophil Renal Cell Carcinoma

Search GEO for disease gene expression data for Chromophil Renal Cell Carcinoma.

Pathways for Chromophil Renal Cell Carcinoma

GO Terms for Chromophil Renal Cell Carcinoma

Sources for Chromophil Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....